I believe Prima licensed the MUC-1 antigen from Oncothyreon, not the other way around.
But yes, any success of theirs would be an additional validation of the MUC-1 target (in addition to the ICS data)
However, Prima's personalised vaccine approach is more compelling and potentially more effective.
So if Stimuvax results are great, then we should benefit. If they're underwhelming, it wouldn't help but it won't be game over for Prima.
- Forums
- ASX - By Stock
- IMM
- watch this space
watch this space, page-10
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
32.0¢ |
Change
0.020(6.67%) |
Mkt cap ! $464.8M |
Open | High | Low | Value | Volume |
30.5¢ | 32.3¢ | 30.0¢ | $1.040M | 3.328M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 31.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
32.0¢ | 42705 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 0.315 |
2 | 99831 | 0.310 |
3 | 120000 | 0.305 |
1 | 30000 | 0.295 |
3 | 13890 | 0.290 |
Price($) | Vol. | No. |
---|---|---|
0.325 | 10000 | 1 |
0.330 | 167144 | 3 |
0.335 | 33333 | 1 |
0.340 | 11336 | 2 |
0.345 | 19800 | 1 |
Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |